Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol plasma concentrations in morbidly obese patients undergoing bariatric surgery
ChiCTR2500102263Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of propofol in obesity, type 2 diabetes mellitus (T2DM), hypertension (HTN) and 5 more, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Plasma concentration of propofol. Started May 2025; status: recruiting.
02
Drugs
propofol
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)hypertension (HTN)cardiac diseasesleep apnea
Beyond the preview
Go deeper on ChiCTR2500102263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102263.